Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Drug shows activity against brain metastases


Lapatinib shrinks some tumors from spread of breast cancer


Nancy Lin, MD

The drug lapatinib shrank tumors and slowed progression of brain metastases in some patients with advanced breast cancer, according to results of a clinical trial being presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Clinical Oncology.

Researchers said the drug, also known as Tykerb, should undergo further testing in combination with other drugs as a treatment for breast cancer that has spread to the brain.

"Results of this study indicate that lapatinib, when given alone, has modest but real activity against brain metastases in women who have had multiple prior treatments for their breast cancer," said Dana-Farber's Nancy Lin, MD, the study's lead author.

The trial examined the tolerability and efficacy of lapatinib in a Phase II study that included 241 patients who had been treated with the drug Herceptin for stage IV HER2-positive breast cancer, and had developed metastases to the brain. About 30 to 40 percent of women treated with Herceptin for stage IV breast cancer are diagnosed with brain metastases.

Brain tumors shrank significantly in what was termed a "partial response" in 15 patients (6 percent). Across all 241 patients, there was a period averaging 15 weeks before the disease progressed again. About one-fifth of patients did not experience any worsening of their disease for 6 months or longer.

Eric Winer, MD, of Dana-Farber, is the study's senior author. Other authors are from centers in several European countries, and from GlaxoSmithKline.

Data from all 241 patients was presented at the ASCO meeting.

"Our data provides evidence that lapatinib has activity based on tumor volume reductions in some patients with progressive HER2-positive disease of the central nervous system after being treated with Herceptin and radiation," the researchers said.

Dana-Farber Cancer Institute ( is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

10/28/2016 11:52:55 AM
  •   Email
  •   Print
  •   Share
  • Media Contacts

    • For all inquiries, call 617-632-4090 and ask to speak to a member of the media team. Please direct emails to
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online